Table 3.
Association of SCD with demographical and clinical variables: Multivariate logistic regression analyses
| OR (95% CI) | p-value | |
|---|---|---|
| Age | 1.03 (0.99–1.08) | 0.131 |
| Sex (male/female) | 0.88 (0.40–1.95) | 0.749 |
| Episodic/chronic headache | 0.97 (0.17–5.43) | 0.968 |
| Migraine types (with aura/without aura/chronic/probable) | 0.73 (0.35–1.51) | 0.392 |
| Frequency of attacks per month | 1.02 (0.95–1.09) | 0.568 |
| Maximum pain duration in hours | 0.994 (0.983–1.006) | 0.331 |
| Number of tablets per month | 1.02 (0.95–1.09) | 0.590 |
| Pain intensity on VAS | 1.14 (0.90–1.45) | 0.268 |
| HIT-6 | 1.00 (0.94–1.07) | 0.887 |
| K-MMSE | 1.02 (0.75–1.37) | 0.919 |
| K-MoCA | 1.09 (0.85–1.38) | 0.507 |
| GAD-7 | 0.96 (0.86–1.07) | 0.492 |
| PHQ-9 | 1.31 (1.16–1.49) | <0.001 |
| PSQI | 0.92 (0.82–1.03) | 0.161 |
| Average Sleeping hours during weekdays | 0.66 (0.44–0.97) | 0.036 |
| Average Sleeping hours during weekends | 1.02 (0.77–1.34) | 0.913 |
VAS Visual Analogue Scale, HIT-6 Headache Impact Test-6, SCD subjective cognitive decline, K-MMSE Korean-Mini Mental State Examination, K-MoCA Korean-Montreal Cognitive Assessment, GAD-7 The Generalized Anxiety Disorder-7, PHQ-9 The Patient Health Questionnaire-9, PSQI The Pittsburgh Sleep Quality Index